Johnson & Johnson (NYSE:JNJ) Shares Sold by CapWealth Advisors LLC

CapWealth Advisors LLC trimmed its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 157,452 shares of the company’s stock after selling 810 shares during the period. Johnson & Johnson comprises approximately 3.4% of CapWealth Advisors LLC’s holdings, making the stock its 5th largest holding. CapWealth Advisors LLC’s holdings in Johnson & Johnson were worth $25,721,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC boosted its holdings in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. GQG Partners LLC boosted its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after purchasing an additional 2,093,392 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of Johnson & Johnson stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 16,410 shares of Johnson & Johnson stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,366,753.62. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock worth $40,960,735 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $168.31 on Wednesday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The firm’s fifty day simple moving average is $175.98 and its 200 day simple moving average is $171.06. The firm has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Johnson & Johnson’s revenue was down 4.4% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. SVB Leerink cut their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Sanford C. Bernstein cut their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Raymond James cut their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 19th. Finally, Bank of America cut their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.